Full Text View
Tabular View
No Study Results Posted
Related Studies
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
This study has been completed.
Study NCT00071838   Information provided by National Institutes of Health Clinical Center (CC)
First Received: October 31, 2003   Last Updated: October 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Daclizumab
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Institute of Neurological Disorders and Stroke (NINDS)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services